BR112017019773A2 - compostos heterocíclicos tricíclicos substituídos - Google Patents
compostos heterocíclicos tricíclicos substituídosInfo
- Publication number
- BR112017019773A2 BR112017019773A2 BR112017019773-1A BR112017019773A BR112017019773A2 BR 112017019773 A2 BR112017019773 A2 BR 112017019773A2 BR 112017019773 A BR112017019773 A BR 112017019773A BR 112017019773 A2 BR112017019773 A2 BR 112017019773A2
- Authority
- BR
- Brazil
- Prior art keywords
- heterocyclic compounds
- compounds
- tricyclic heterocyclic
- cr3r3
- substituted tricyclic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101150033527 TNF gene Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134769P | 2015-03-18 | 2015-03-18 | |
| US62/134,769 | 2015-03-18 | ||
| PCT/US2016/022737 WO2016149436A1 (en) | 2015-03-18 | 2016-03-17 | Substituted tricyclic heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017019773A2 true BR112017019773A2 (pt) | 2018-05-15 |
Family
ID=55640932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017019773-1A BR112017019773A2 (pt) | 2015-03-18 | 2016-03-17 | compostos heterocíclicos tricíclicos substituídos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10189840B2 (https=) |
| EP (1) | EP3271360B1 (https=) |
| JP (1) | JP6793657B2 (https=) |
| KR (1) | KR102654709B1 (https=) |
| CN (1) | CN107635993B (https=) |
| AU (1) | AU2016233288A1 (https=) |
| BR (1) | BR112017019773A2 (https=) |
| CA (1) | CA2980159A1 (https=) |
| EA (1) | EA032315B1 (https=) |
| ES (1) | ES2797805T3 (https=) |
| IL (1) | IL254424A0 (https=) |
| MX (1) | MX2017011434A (https=) |
| SG (1) | SG11201707469WA (https=) |
| WO (1) | WO2016149436A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016149439A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Heterocyclic compounds useful as inhibitors of tnf |
| ES2797685T3 (es) | 2015-03-18 | 2020-12-03 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF |
| EP3288939A1 (en) | 2015-04-17 | 2018-03-07 | AbbVie Inc. | Tricyclic modulators of tnf signaling |
| WO2016168633A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| BR112018001980A2 (pt) | 2015-08-03 | 2018-09-18 | Bristol Myers Squibb Co | compostos cíclicos úteis como moduladores de tnf alfa |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CN110461842A (zh) * | 2017-03-15 | 2019-11-15 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6038397B2 (ja) * | 1980-03-06 | 1985-08-31 | エスエス製薬株式会社 | チアジノイミダゾ−ル誘導体及びその製造法 |
| CA2281927C (en) | 1997-02-25 | 2004-01-27 | Christopher J. Michejda | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase |
| ATE311385T1 (de) * | 1999-10-27 | 2005-12-15 | Novartis Pharma Gmbh | Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika |
| US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
| JPWO2003064422A1 (ja) | 2002-01-31 | 2005-05-26 | 第一製薬株式会社 | イミダゾ［１，２−ａ］ピリジン誘導体 |
| AU2003298839A1 (en) | 2002-12-03 | 2004-06-23 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| BRPI0813273A2 (pt) * | 2007-06-26 | 2014-12-30 | Sanofi Aventis | Síntese catalisada por metal regiosseletivo de benzimidazóis e azabenzimidazóis anelados |
| FR2919610B1 (fr) * | 2007-08-02 | 2009-10-16 | Sanofi Aventis Sa | Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique |
| EP2209785A1 (en) | 2007-10-05 | 2010-07-28 | S*BIO Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| JP2009227599A (ja) | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | イミダゾピリダジン誘導体 |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| JP5487214B2 (ja) * | 2008-12-19 | 2014-05-07 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 |
| CN103739605B (zh) | 2009-03-23 | 2016-08-17 | 伊莱利利公司 | 用于检测神经障碍的显像剂 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| CN104619709B (zh) | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| US9920052B2 (en) | 2013-12-09 | 2018-03-20 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of TNF activity |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| RU2685234C1 (ru) | 2013-12-09 | 2019-04-17 | Юсб Байофарма Спрл | Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf |
| GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| MX388321B (es) | 2014-10-06 | 2025-03-19 | Signal Pharm Llc | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. |
| ES2797685T3 (es) | 2015-03-18 | 2020-12-03 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF |
| WO2016149439A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Heterocyclic compounds useful as inhibitors of tnf |
-
2016
- 2016-03-17 CN CN201680026733.XA patent/CN107635993B/zh active Active
- 2016-03-17 EP EP16712645.7A patent/EP3271360B1/en active Active
- 2016-03-17 SG SG11201707469WA patent/SG11201707469WA/en unknown
- 2016-03-17 CA CA2980159A patent/CA2980159A1/en not_active Abandoned
- 2016-03-17 US US15/558,692 patent/US10189840B2/en active Active
- 2016-03-17 JP JP2017549092A patent/JP6793657B2/ja active Active
- 2016-03-17 EA EA201792034A patent/EA032315B1/ru not_active IP Right Cessation
- 2016-03-17 AU AU2016233288A patent/AU2016233288A1/en not_active Abandoned
- 2016-03-17 BR BR112017019773-1A patent/BR112017019773A2/pt not_active Application Discontinuation
- 2016-03-17 WO PCT/US2016/022737 patent/WO2016149436A1/en not_active Ceased
- 2016-03-17 MX MX2017011434A patent/MX2017011434A/es unknown
- 2016-03-17 ES ES16712645T patent/ES2797805T3/es active Active
- 2016-03-17 KR KR1020177029449A patent/KR102654709B1/ko active Active
-
2017
- 2017-09-11 IL IL254424A patent/IL254424A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3271360B1 (en) | 2020-04-22 |
| ES2797805T3 (es) | 2020-12-03 |
| IL254424A0 (en) | 2017-11-30 |
| JP6793657B2 (ja) | 2020-12-02 |
| KR102654709B1 (ko) | 2024-04-03 |
| CN107635993B (zh) | 2020-05-22 |
| CN107635993A (zh) | 2018-01-26 |
| KR20170129810A (ko) | 2017-11-27 |
| EP3271360A1 (en) | 2018-01-24 |
| EA032315B1 (ru) | 2019-05-31 |
| CA2980159A1 (en) | 2016-09-22 |
| US10189840B2 (en) | 2019-01-29 |
| WO2016149436A1 (en) | 2016-09-22 |
| EA201792034A1 (ru) | 2018-03-30 |
| SG11201707469WA (en) | 2017-10-30 |
| AU2016233288A1 (en) | 2017-11-09 |
| MX2017011434A (es) | 2018-01-25 |
| JP2018508553A (ja) | 2018-03-29 |
| US20180111936A1 (en) | 2018-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017019773A2 (pt) | compostos heterocíclicos tricíclicos substituídos | |
| CL2019000588A1 (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tlr. | |
| BR112019003415A2 (pt) | compostos de pirrolizina substituídos e usos dos mesmos | |
| BR112018001960A2 (pt) | compostos heterocíclicos úteis como moduladores de tnf alfa | |
| BR112017002942A2 (pt) | compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53 | |
| EA202091480A1 (ru) | Аминоиндольные соединения, пригодные в качестве ингибиторов tlr | |
| BR112019005595A2 (pt) | compostos e métodos para modulação de ido e tdo, e indicações para os mesmos | |
| BR112018076534A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| MX2018012609A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| BR112017019731A2 (pt) | compostos heterocíclicos tricíclicos úteis como inibidores de tnf | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201791692A1 (ru) | 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ | |
| CL2017002332A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| BR112016019462B8 (pt) | Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase | |
| EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| BR112012017269A2 (pt) | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos | |
| BR112015022861A2 (pt) | inibidores de bromodomínio | |
| BR112017001334A2 (pt) | compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende | |
| EA201691044A1 (ru) | Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил | |
| EA201892246A1 (ru) | Производные аминотиазола, полученные в качестве противовирусных средств | |
| BR112017019605A2 (pt) | compostos heterocíclicos úteis como inibidores de tnf | |
| BR112018001980A2 (pt) | compostos cíclicos úteis como moduladores de tnf alfa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |